EC Number   |
Natural Substrates   |
---|
  1.3.1.21 | 7-dehydrodesmosterol + NADPH |
- |
  1.3.1.21 | 7-dehydrodesmosterol + NADPH |
terminal step in desmosterol de novo biosynthesis, pathway and physiological role, overview |
  1.3.1.21 | cholesta-5,7-dien-3-beta-ol + NADPH |
- |
  1.3.1.21 | cholesta-5,7-dien-3-beta-ol + NADPH |
highly regiospecific for DELTA7-bond reduction, but wide substrate specificity |
  1.3.1.21 | cholesta-5,7-dien-3-beta-ol + NADPH |
defect in cholesterol biosynthesis cause multiple congenital, developmental and morphogenic anomalies, e.g. the Smith-Lemli-Opitz syndrome due to a gene mutation, overview |
  1.3.1.21 | cholesta-5,7-dien-3-beta-ol + NADPH |
cholesterol formation outside myelin sheath |
  1.3.1.21 | cholesta-5,7-dien-3-beta-ol + NADPH |
cholesterol biosynthesis |
  1.3.1.21 | cholesta-5,7-dien-3-beta-ol + NADPH |
reversibility of the reaction in vivo could not be proven |
  1.3.1.21 | cholesta-5,7-dien-3beta-ol + NADPH |
- |
  1.3.1.21 | cholesta-5,7-dien-3beta-ol + NADPH |
enzyme catalyzes the terminal step in cholesterol biosynthesis by reducing 7-dehydrocholesterol |